NSCLC Biomarker Testing: This course reviews current guidelines and strategies for biomarker testing in advanced NSCLC.
The NSCLC ONCOdriver Therapy Tool provides expert recommendations for the management of patients with non-small cell lung cancer (NSCLC) based on molecular biomarker testing and the presence of actionable oncodriver mutations (eg, ALK, ROS1). To support healthcare professionals in the effective use of the tool, the clinical resources listed below offer concise summaries of key aspects of biomarker-directed care.
The tool integrates guideline recommendations on biomarker testing and NSCLC treatment from the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), and National Comprehensive Cancer Network (NCCN).
With rapid advances in cancer treatment, oncologists and their clinical teams are challenged to keep pace with the latest evidence and standards of care. The Oncology Clinic Companion provides independent medical education and practical tools designed to increase knowledge, competence and performance among oncology professionals. About Oncology Clinic Companion.
The brief knowledge-building modules review essential topics in immuno-oncology (IO), including the immune system and cancer therapy, mechanisms of action of immune checkpoint inhibitors, assessing response to IO therapy and immune-related adverse events.
The case challenges explore the role of checkpoint inhibitor therapy in the management of cancer, including advanced renal cancer, advanced bladder cancer, advanced melanoma and Hodgkin lymphoma.
The webcast modules, recorded at the ECOS 2019 meeting, feature cardio-oncology experts holding multidisciplinary sessions with interactive discussion and case reviews.
Test and build your knowledge of core concepts in immuno-oncology (IO) therapy with challenging patient cases in cancer, including bladder, lung, colorectal and kidney cancer, as well as lymphoma and melanoma.
What is the future of IO therapy in renal and bladder cancers? Listen as EIOCC faculty Maria Carmen Mir, MD, PhD, and Mario W. Kramer, MD, discuss the emerging role of immune checkpoint inhibitors in patient care.
A Division of Siyemi Europe